Related Experiment Videos
[Cancer-associated gene abnormalities and chemosensitivity]
M Sakamoto1, K Umayahara, H Sakamoto
1Dept. of Gynecology, Sasaki Institute Kyoundo Hospital, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 3, 1998
Summary
Predicting cancer chemotherapy effectiveness is crucial. New genetic markers, like Xp and 19q in ovarian cancer, can identify drug resistance, guiding personalized treatment strategies.
Area of Science:
- Oncology
- Cancer Genomics
- Pharmacogenomics
Context:
- Chemotherapy resistance is a major clinical challenge in cancer treatment.
- Identifying reliable markers for chemoresistance is essential for effective patient management.
- Existing methods for predicting chemoresistance include empirical data and direct testing.
Purpose:
- To review known chemo-sensitivity markers and discovery methodologies.
- To investigate potential genetic markers associated with cisplatin resistance in ovarian cancer.
- To identify novel genetic markers for predicting chemotherapy response.
Summary:
- This study reviews chemo-sensitivity markers and their discovery. Comparative Genomic Hybridization (CGH) analysis of ovarian cancer cases revealed copy number decrease in Xp and copy number increase in 19q were significantly associated with cisplatin resistance.
- These genetic alterations (-Xp and +19q) suggest a role in intrinsic drug resistance, offering potential biomarkers for predicting treatment outcomes.
- The findings contribute to the ongoing effort to discover new chemo-sensitivity and resistance markers.
Impact:
- Enables prediction of chemotherapy effectiveness and necessity before treatment initiation.
- Facilitates the development of personalized medicine approaches in cancer therapy.
- Advances the understanding of genetic underpinnings of chemoresistance, paving the way for novel therapeutic strategies.